1. Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study
- Author
-
Svetlana Yu. Chikina, Andrey I. Yaroshetskiy, Tatiana Yu. Gneusheva, Galia S. Nuralieva, Galina Nekludova, Zamira M. Merzhoeva, Sergey Avdeev, Natalia A. Tsareva, Anna E. Shmidt, Natalia V. Trushenko, and Olga A. Suvorova
- Subjects
Diarrhea ,Male ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,medicine.drug_class ,Short Communication ,medicine.medical_treatment ,Immunology ,Pilot Projects ,Therapeutics ,Cytokine storm ,Antibodies, Monoclonal, Humanized ,Monoclonal antibody ,Severity of Illness Index ,Biochemistry ,law.invention ,Netakimab ,law ,Internal medicine ,medicine ,Humans ,Immunology and Allergy ,Molecular Biology ,Aged ,Retrospective Studies ,Inflammation ,Mechanical ventilation ,Inpatients ,SARS-CoV-2 ,business.industry ,Interleukin-17 ,COVID-19 ,Hematology ,Oxygenation ,Length of Stay ,Middle Aged ,medicine.disease ,Respiration, Artificial ,Intensive care unit ,Pathophysiology ,Hospitalization ,IL-17 ,Dyspnea ,Treatment Outcome ,Case-Control Studies ,Female ,Interleukin 17 ,business - Abstract
Background One of the main pathophysiological mechanisms underlying the severe course of COVID-19 is the hyper-inflammatory syndrome associated with progressive damage of lung tissue and multi-organ dysfunction. IL-17 has been suggested to be involved in hyper-inflammatory syndrome. Objective To evaluate the efficacy and safety of the IL-17 inhibitor netakimab in patients with severe COVID-19. Study design. In our retrospective case-control study we evaluated the efficacy of netakimab in hospitalized patients with severe COVID-19 outside the intensive care unit (ICU). Patients in the experimental group were treated with standard of care therapy and netakimab at a dose of 120 mg subcutaneously. Results 171 patients with severe COVID-19 were enrolled in our study, and 88 of them received netakimab. On the 3 day of therapy, body temperature, SpO2/FiO2, NEWS2 score, and CRP improved significantly in the netakimab group compared to the control group. Other clinical outcomes such as transfer to ICU (11.4% vs 9.6%), need for mechanical ventilation (10.2% vs 9.6%), 28-day mortality (10.2% vs 8.4%), did not differ between the groups. Conclusion In hospitalized patients with severe COVID-19, anti-IL-17 therapy might mitigate the inflammatory response and improve oxygenation, but do not affect the need for mechanical ventilation and mortality.
- Published
- 2021